Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate
SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility (“DF”) study in addition to its previously announced dosing validation (“DV”) study …